News | June 09, 2022
National Ayurveda Research Institute for Panchakarma bags NABL Accreditation
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
AstraZeneca also played a critical role in the global response to COVID-19.
Innate to receive $5M milestone payment from AstraZeneca
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Subscribe To Our Newsletter & Stay Updated
